BridgeBio Pharma BBIO 深 滬
等待開盤 08-14 09:30:00 美东时间
50.38
+1.290
+2.63%
華盛通- 最 高50.51
- 今 開49.60
- 成交量 222.24万股
- 最 低 49.105
- 昨 收 49.09
- 總市值 95.72亿
- 52周最高 50.51
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 21.72
- 委 比 -31.90%
- 總股本 1.90亿
- 歷史最高 73.50
- 量 比 0.47
- 振 幅 2.86%
- 歷史最低 4.98
- 每 手 1
- 風險率 7.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
Oppenheimer Maintains Outperform on BridgeBio Pharma, Raises Price Target to $61
Oppenheimer analyst Leland Gershell maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $60 to $61.
08-06 20:10
Helix Acquisition Corp. II Retains 60% Trust Funds
Helix Acquisition Corp. II Class A ( ($HLXB) ) just unveiled an announcement. O...
08-06 19:59
Helix SPAC Keeps $120M in Trust as Merger With Cancer Drugmaker BBOT Moves Ahead With $382M in Funding
Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a
08-06 19:38
BridgeBio Pharma shares are trading lower after the company reported worse-than-expected Q2 EPS results.
BridgeBio Pharma shares are trading lower after the company reported worse-than...
08-06 04:05
BridgeBio Pharma Q2 EPS $(0.95) Misses $(0.81) Estimate, Sales $110.565M Beat $100.424M Estimate
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.81) by 17.43 percent. This is a 10.38 percent increase over losses of $(1.06) per share
08-06 04:02
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
BridgeBio Pharma published a study in the American Journal of Human Genetics confirming the genetic prevalence of autosomal dominant hypocalcemia type 1 (ADH1) and highlighting a significant gap in diagnosis. The study found that approximately 25,000 individuals in the U.S. and EU carry ADH1-causing variants, but only 20% of those with genetic links to ADH1 have been diagnosed. Nine novel gain-of-function CASR variants were identified, further su...
07-23 11:30
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
BridgeBio Pharma will announce its second quarter financial results and updates on August 5, 2025, after the market close. A conference call at 4:30 pm ET will discuss the results, with live webcast access available via investor.bridgebio.com. A replay will be available for 30 days. The company, focused on genetic diseases, provides transformative medicines and updates on its pipeline. Media and investor contacts are provided.
07-22 11:30
Truist Securities Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $66
Truist Securities analyst Danielle Brill initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and announces Price Target of $66.
07-21 19:56
